Company intelligence / Profile preview
BioAegis Therapeutics
North Brunswick, New Jersey, United Statesbioaegistherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
BioAegis Therapeutics’ lead asset—recombinant human plasma gelsolin—is in a global Phase 2 trial for moderate-to-severe ARDS. The study involves over 600 patients across multiple countries and aims to demonstrate efficacy in improving survival without organ failure at Day 28. The company’s approach has shown promise as a non-immunosuppressive anti-inflammatory therapy that restores innate immune balance and may address high unmet needs in severe inflammatory conditions. Early results have supported safety and mechanistic rationale; pivotal efficacy data are pending from the ongoing trial.[6][8]
- Therapeutic areas
- ImmunologyPulmonologyNeurologyInfectious Diseases
- Modalities
- Recombinant proteins (notably recombinant human plasma gelsolin, rhu-pGSN)[1][4][10]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
BARDA – $20 million contract to support ARDS clinical development of rhu-pGSN [6][10]
Beyond the preview
Go deeper on BioAegis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioAegis Therapeutics.